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Tularemia with peritonitis developed in a 50-year-old
man soon after diagnosis of stomach cancer with metasta-
sis. The ascites grew Francisella tularensis subsp. holarc-
tica, which was identified by sequencing analysis of the
16S rDNA. The infection resolved with antimicrobial treat-
ment. Antibodies detected 4 weeks after onset disap-
peared after chemotherapy-associated lymphopenia. 
Case Study
A 50-year-old man arrived at the emergency depart-
ment in September 2003 with a 2-day history of high fever
(temperature up to 40.8°C), rigors, dry cough, nausea,
vomiting, lower abdominal pain, and melena. The patient
had recently been diagnosed with signet-ring–cell carcino-
ma of the stomach with evidence of metastasis to the lung
and peritoneum and multiple thoracic and abdominal
lymph nodes. Chemotherapy had been planned to start
soon. 
Physical examination showed fever (temperature
39.7°C), hypotension (96/51 mm Hg), a systolic heart mur-
mur with regular rhythm, and lower abdominal tenderness
and rebound. Laboratory examination showed microcytic
anemia (hemoglobin 87 g/L), relative neutrophilia (82% of
7.8 x 109/L total leukocytes), and relative and absolute
lymphopenia (7% of leukocytes or 0.55 x 109/L). A chest
x-ray was normal, as were liver function tests and pancre-
atic enzymes. Apresumptive diagnosis of sepsis with peri-
tonitis was made, and blood and urine were collected for
cultures. Empiric cefepime (2 g every 8 h) and tobramycin
(one dose 500 mg) therapy was started before hospital
admission.
The following day, an esophagogastroduodenoscopy
showed cancer ulceration as the source of melena. An
echocardiography excluded endocarditis. An abdominal
sonogram showed small pockets of ascites in the abdomen
and pelvis, and the fluid showed many neutrophils, lym-
phocytes, and macrophages, consistent with peritonitis.
The ascites (5 mL) was also cultured. Despite cefepime
treatment, the patient’s fever persisted for 36 hours, which
prompted a change to imipenem (500 mg every 6 h) and
vancomycin (1 g every 12 h). The fever subsided in 1 day,
as did the abdominal manifestations. The patient was dis-
charged the following day with further oral gatifloxacin
(400 mg four times a day) and amoxicillin/clavulanate
(875 mg twice a day) for 10 days. 
Anticancer therapy that consisted of radiation to the
stomach and daily capecitabine and weekly paclitaxel was
begun 5 days after discharge. Two weeks later, at comple-
tion of these treatments and the oral antimicrobial drugs,
the abdominal lymphadenopathy showed improvement on
computed tomography. However, the tumor itself, as well
as the lung nodules, remained stable. Additional
chemotherapy with three cycles of paclitaxel and carbo-
platin was started soon afterwards. 
Meanwhile, the ascites culture (Bactec Aerobic/F bottle
with resins) became positive after 8 days of incubation,
and a small gram-negative coccobacillus (strain
MDA3270) was isolated. Its fastidious growth and unusu-
al Gram stain features prompted sequencing analysis of the
16S rDNA for identification (1). A 586-base pair DNA
fragment, amplified by polymerase chain reaction, demon-
strated 100% sequence homology with Francisella
tularensis  subsp. holarctica (GenBank accession no.
L26086, Wilson et al., unpub. data, and AF227312) (2). On
review, the culture and stain features fit F. tularensis. The
subspecies was confirmed by the Centers for Disease
Control and Prevention (CDC) (Fort Collins, CO). The
blood culture remained negative after 7 days of incubation.
The diagnosis of typhoidal tularemia (24 days after
onset) led the patient to be further treated with intravenous
gentamicin for 2 weeks (120 mg every 8 h), followed by 2
weeks of oral ciprofloxacin (750 mg twice a day). A query
of exposure history was also made. The patient was a
farmer from northeastern Mississippi and had cut hay in a
field infested with rodents 3 weeks before onset. He had
traveled from home to Houston for the cancer care. The
patient had no history of camping, hunting, or bites by
ticks or deerflies. After 6 weeks of anticancer therapy (7
weeks after tularemia), the patient’s carcinoembryonic
antigen decreased substantially. However, a predominant
6-cm mass in the gastrohepatic ligament region persisted,
which raised the question of infection versus cancer. Thus,
a percutaneous needle biopsy was performed, and cancer-
ous mucin was demonstrated. Further chemotherapy con-
tinued.
A convalescent antibody against F. tularensis was
detected 4 weeks after onset (titer 1:40, direct agglutina-
tion method); however, it disappeared at 3 months after
chemotherapy-associated lymphopenia (Figure). Before
chemotherapy started, the lymphocyte counts had been
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Texas, USA1.0 x 109/L before infection, 0.55–0.40 x 109/L in early
infection, and 1.94 x 109/L 8 days postonset. After
chemotherapy, however, the counts dropped sharply to 0.07
x 109/L (96% reduction) in 2 weeks. During the remaining
weeks of therapy, lymphopenia persisted despite improve-
ment. In contrast, the patient’s neutrophil counts were nor-
mal to slightly elevated during the entire course. 
Conclusions
The interest in tularemia and its pathogen, F. tularensis,
is renewed due to the high bioterrorism potential of the
organism, i.e., listed as a category A by CDC
(www.bt.cdc.gov).  F. tularensis, a gram-negative coc-
cobacillus, survives well in the environment and is faculta-
tive in infected host cells (macrophages). It has a high
infectivity rate and is zoonotic. Human infection occurs
mainly in animal handlers and those who are bitten by
ticks, deerflies, or both. Airborne and waterborne out-
breaks have also been reported (2–4). From 1990 to 2001,
a total of 1,497 tularemia cases was reported to CDC
(mean 125 cases per year), with 55% occurring in the
states of Arkansas, Missouri, South Dakota, and Oklahoma
(5,6). During those 12 years, however, Mississippi, the
home state of our patient, had only one case. In view of the
highest disease activity in neighboring Arkansas (324
cases), underreporting of the disease in Mississippi was a
possibility in addition to other explanations, such as geo-
graphic differences and barriers (Mississippi River). 
Tularemia manifests a few clinical forms and, before
the antimicrobial era, carried a high fatality rate. The diag-
nosis of tularemia is often difficult to make, especially for
the typhoidal and pneumonic forms. Most cases are diag-
nosed by serologic tests late in infection or afterwards. In
an epidemiologic study of >1,000 cases (7), only 11% were
diagnosed by isolation of F. tularensis from a body source,
such as ulcer fluid, blood, lymph node aspirate, and pleu-
ral fluid. With improved blood culture methods in the past
2 decades, however, cases of F. tularensis bacteremia have
been reported (3,8–14). These blood cultures became pos-
itive after an incubation period of 3 days to 3 weeks (medi-
an 7 days). Most cases were in patients with underlying
conditions or diseases, such as old age, alcohol abuse, dia-
betes mellitus, transplantation, or AIDS. The immunocom-
promised patients tend to have prolonged infection or die.
In a syngeneic bone marrow transplant patient (15), the
infection presented as a 3-cm solitary pulmonary nodule,
and after 6 weeks of antimicrobial treatment, the culture-
positive nodule vanished. 
Tularemia with associated peritonitis is extraordinary
rare. Our patient’s peritonitis was likely related to metasta-
tic stomach cancer that had breached the integrity of peri-
toneum and regional blood vessels and lymph nodes,
leading to peritoneal spill of the organism (free or intra-
macrophage ones). The ascites did contain many
macrophages. To combat the infection, neutrophilia devel-
oped. Because the patient was severely anemic, absolute
lymphopenia developed from normal baseline (Figure).
Lymphopenia is generally absent in tularemia, and this
patient’s response was likely a compromise for neutrophil-
ia. However, the lymphocyte count rebounded a few days
later. The patient’s response to cefepime therapy was sub-
optimal in view of the persistence of fever and concurrent
isolation of the organism. Streptomycin or gentamicin, not
a cephalosporin, is recommended to treat tularemia.
Successful treatment with a fluoroquinolone has also been
reported in at least 10 recent cases (11). The source of
infection could not be determined definitively; however,
living and working in a farm and the history of exposure to
rodent-infested hay were probably important. Recently,
landscaping occupation, such as lawn mowing and weed-
whacking, is recognized as a risk for exposure (16). 
The antibody response against tularemia is usually
strong, peaking at 2–3 months after onset (2). In an out-
break caused by F. tularensis subsp. holarctica, the peak
titer reached 1:256 to 1:8,192 (median 1:1,024) (2). In our
patient, urgent initiation of the lymphotoxic anticancer
chemotherapy blunted the initial response by ablating the
antibody-producing lymphocytes. One of the agents,
capecitabine, causes lymphopenia in >90% of patients fol-
lowing treatment (17). During the 11-week chemotherapy,
existing antibodies (titer 1:40) were degraded in the circu-
lation (3–4 half-lives) and became undetectable.
Therefore, this case illustrates that, after anticancer
chemotherapy, lack of antibody does not exclude an infec-
tion that usually elicits antibody response. 
F. tularensis has four subspecies (biovars): tularensis,
holarctica, novicida, and mediasiatica, and the first two
subspecies are the main causes of tularemia in the United
States. F. tularensis subsp. holarctica, also known as type
B or biovar palaearctica, is generally less virulent than
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Figure. Effect of tularemia and anticancer chemotherapy on the
lymphocyte counts and antibody response in a patient with gastric
cancer.F. tularensis subsp. tularensis (type A). Both typhoidal and
cutaneous forms have been reported for F. tularensis
subsp. holarctica (2,3,9,11,13,14). For the typhoidal cases,
including ours, all nine reported patients recovered, and
the median incubation of blood cultures was 9 days (4
days–3 weeks) (3,9,11,13,14), similar to the 8 days in our
ascites culture.
Identifying F. tularensis may be difficult because of its
rarity and fastidious growth, especially in areas where dis-
ease is nonendemic. Our laboratory has been using the 16S
rDNA sequencing method to identify mycobacteria and
other fastidious organisms. The method is considered to be
the single best method to identify bacteria and will likely
impact patient care in addition to microbiologic research. 
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